Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Expert Rev Vaccines. 2016 May 27;15(9):1101–1112. doi: 10.1080/14760584.2016.1187566

Table 1.

Overview of Ebola virus disease candidate vaccines under clinical investigation.

Vaccine Class Vaccine Name Manufacturer or
sponsor		 Most Advanced
Clinical Trial
Status* 		Pros Cons Comments
Vectored,
Live 		rVSV-ZEBOV [12–
14,17–19,21,22]		 Merck Sharp & Dohme
Corp, NewLink Genetics,
Public Health Agency of
Canada		 Phase 3 Single vaccination is
highly immunogenic		 Some safety
concerns
HPIV3-EbovZ GP
[30–32]		 NIAID Phase 1 Intranasal
administration may
elicit more robust
mucosal immunity		 Pre-existing
immunity to
vector
Vectored,
non-
replicating 		ChAd3.EBOZ /
ChAd3.EBO [52–
57]		 Glaxo Smith Kline, NIAID Phase 2 Safety Requires boost
vaccination
Ad26.ZEBOV
[40,63]		 Crucell Holland BV
(Johnson & Johnson)		 Phase 3 Safety Requires boost
vaccination		 Phase 4 retrospective
evaluation underway
though product is not
licensed
(NCT02661464)
Ad5-EBOV [65,66] Tianjin CanSino
Biotechnology and Beijing
Institute of Biotechnology		 Phase 2 Pre-existing
immunity to Ad5
vector		 Requires boost
vaccination
VRC-
EBOADV018-00-
VP [38,39]		 NIAID Phase 1 Pre-existing
immunity to Ad5
vector		 Requires boost
vaccination		 No longer active
MVA-BN-Filo [54] Bavarian Nordic GmbH /
Crucell Holland BV
(Johnson & Johnson)		 Phase 3 Safety Immunogenicity;
Requires
heterotypic pairing
for vaccine
administration		 Phase 4 retrospective
evaluation underway
though product is not
licensed
(NCT02661464)
MVA-EbolaZ
(VRC-
EBOMVA079-00-
VP)[52]		 NIAID Phase 1 Safety Immunogenicity;
Requires
heterotypic pairing
for vaccine
administration
DNA VRC-
EBODNA023-00-
VP,
VRCEBODNA012-
00-VP, and
VRCMARDNA025-
00-VP [49,77–79]		 NIAID Phase 1 Safety, flexible
platform, low cost		 Effective
administration
requires
electroporation
technology;
requires boost
vaccination for
immunogenicity		 No longer active
INO-4201, -4202,
and -4212 [no
publications yet]		 Inovio Pharmaceuticals,
GeneOne Life Science Inc.,
DARPA		 Phase 1 Safety, flexible
platform, low cost		 Effective
administration
requires
electroporation
technology;
requires boost
vaccination for
immunogenicity
Subunit /
Protein 		EBOVGP1,2 with
Matrix-M [no
publications yet])		 Novavax Phase 1 Pending Phase 1
results, “pro” may
be safety		 Immunogenicity
unclear at time of
publication